查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840838

次世代定序仪样品製备市场：按产品类型、工作流程、NGS技术、样品类型、应用和最终用户划分－2025-2032年全球预测

Next-Generation Sequencing Sample Preparation Market by Product, Workflow, NGS Technology, Sample Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，次世代定序仪样品製备市场规模将达到 145.2 亿美元，复合年增长率为 12.47%。

关键市场统计数据
基准年 2024 56.7亿美元
预计年份：2025年 63.4亿美元
预测年份 2032 145.2亿美元
复合年增长率 (%) 12.47%

了解如何优化样本製备流程，这对于保护资料完整性、加速研究和改善临床定序结果至关重要。

次世代定序仪(NGS) 已从一项革命性的实验室技术发展成为现代生物学、诊断学和应用研究的基石。随着定序通量和分析复杂性的不断提高，定序前的各项流程——包括样本采集、核酸提取、文库建构、标靶富集和品管——已成为数据保真度和可解释性的关键决定因素。稳健的样本製备能够确保所需的生物讯号得以保留并在下游仪器上稳定显示，从而降低分析变异性，并加速将原始序列读段转化为可操作的洞见。

本报告透过分析技术进步、监管审查和营运需求三者如何共同影响学术、临床和商业实验室的实践，强调了样本製备的策略重要性。报告指出，试剂、自动化和方案标准化的改进对週转时间、可重复性和单次结果成本有直接影响。因此，实验室负责人和采购团队必须将样本製备视为定序价值链中不可或缺的一部分，而非仅仅是一项外围的耗材成本。

最后，引言部分透过向相关人员提出关键问题，为深入分析奠定了基础：不同的工作流程和耗材如何影响分析结果？哪些创新能够大幅减少分析前误差？以及各组织应如何优先考虑投资，以满足科学目标和监管要求？在此框架下，后续章节概述了不断变化的市场格局、监管阻力、市场细分资讯、区域动态、竞争格局以及为策略决策提供参考的实用建议。

评估技术创新、自动化和标准化如何重塑样品製备并影响实验室运作模式。

受技术创新、不断变化的法规环境以及终端用户对可重复、高品质资料日益增长的需求驱动，次世代定序仪的样本製备领域正经历着快速且多维度的变革。试剂化学和酵素学的进步使得文库製备更加高效，所需样本量更少，从而拓展了可分析的样本类型。同时，自动化和微流体控技术的改进降低了人为操作的误差，提高了定序通量。随着定序定序扩大到群体层级研究和常规临床诊断，这一点尤其重要。

伴随这项技术变革而来的是对标准化和互通性的日益重视。实验室间可重复性如今已成为临床验证和合作研究的核心指标，促使供应商和实验室投资于检验的套件、封闭式工作流程和整合式品质控制解决方案。湿实验室改进与资讯学赋能的品质查核点的整合，增强了从样本收集到资料交付的可追溯性。此外，标靶序列捕获纯化和低起始量文库构建等新型方法正在催生新的应用，例如循环肿瘤DNA谱分析和单细胞分析，这些应用需要专门的样本製备策略。

因此，各机构正在重新思考其采购和营运模式。目前，市场明显转向整合仪器、试剂和服务的捆绑式解决方案，以最大限度地减少相容性问题并加快测试结果的获取速度。供应商必须证明其产品与工作流程的兼容性以及符合监管要求，而实验室则必须在标准化、检验的套件和平台的效率与客製化通讯协定的灵活性之间取得平衡。最终，这些变革性的变化正在重新定义整个样本製备生态系统中对绩效、可靠性和生命週期支援的期望。

检验关税变化和贸易政策转变对试剂采购、筹资策略和生产连续性造成的营运和供应链影响。

关税变化和贸易政策调整会立即对次世代定序仪製备所需的试剂、设备和耗材的供应链造成压力。在美国，已宣布或将于2025年实施的关税，将为那些从海外供应商采购专用酶、塑胶和仪器零件的公司带来新的成本考量和物流复杂性。这些变化迫使采购团队重新评估供应商合约、前置作业时间缓衝和紧急库存，以降低中断风险并维持服务连续性。

为因应关税带来的不确定性，许多相关人员正在探索区域采购安排，以实现供应商网路多元化并降低跨境关税风险。一些实验室正在加快替代试剂形式和非供应商耗材的认证，以保持营运灵活性。同时，製造商正在调整定价策略，实现部分生产环节的在地化，并扩大经销商伙伴关係，以抵销贸易相关成本的直接影响。此类调整往往会带来过渡期的摩擦，例如认证週期和潜在的批次间性能差异，这些都必须透过严格的品质控制通讯协定来管理。

从营运角度来看，科学研究机构在提昇科研绩效的同时，也优先考虑供应链的韧性。这就要求制定风险评估方案，将关税波动、前置作业时间变化以及对单一供应商的依赖等因素纳入考量。同时，采购和实验室负责人正加强合作，力求在短期保障措施和长期策略采购之间取得平衡，确保样品製备流程在政策和贸易波动持续的情况下依然稳健运作。这种集体因应措施凸显了灵活的筹资策略和供应商合作模式对于维护实验完整性和服务交付的重要性。

提供细緻入微的细分讯息，将产品类型、工作流程、技术、样品类别、应用和最终用户优先顺序连结起来，从而指南采购和开发。

要全面了解样品製备领域，需要从多个细分维度进行深入分析，这些维度会影响采购行为、工作流程设计和技术相容性。基于产品考量，实验室将仪器、试剂和耗材以及服务视为既独立又相互依存的类别，这些类别共同决定了整体工作流程的性能和供应商的价值提案。仪器为通量和自动化设定了技术基准，试剂和耗材控制化学性能和批次一致性，而包括安装和方法验证在内的服务则确保了快速部署和运作可靠性。

从工作流程的角度来看，相关人员关注的是文库製备和扩增、文库定量和品管、核酸萃取以及标靶序列捕获这几个顺序步骤，优化这些步骤能够显着提升资料品质。文库製备和扩增技术对于维持样本代表性和减少偏差至关重要，而稳健的定量和品质控制则能避免代价高昂的定序失败。核酸萃取仍然是基础步骤，萃取效率和抑制剂去除对于后续分析的成功至关重要。同时，标靶富集方法决定了后续分析（针对标靶panel和变异检测）的特异性和灵敏度。

NGS技术的细分进一步细化了决策标准。诸如ChIP定序、EXOME定序、甲基化定序、RNA定序、标靶定序和全基因组定序等方法，各自对输入品质、片段大小和富集策略提出了不同的要求。 DNA和RNA样本类型的细分凸显了不同的处理需求和稳定化通讯协定，其中RNA工作流程通常需要更严格的储存和品质控制。从农业基因组学和动物科学到临床诊断、临床研究、药物开发、消费者基因组学和法医学，应用主导的优先事项正在影响验证要求、通量容差和监管。最后，包括学术和研究机构、医院和诊所以及製药和生物技术公司在内的最终用户，有着独特的采购理由和服务期望，这迫使供应商提供差异化的商业模式和技术支持，以满足这些多样化的需求。

了解区域法律规范、基础设施投资和本地采购趋势如何影响全球区域的采购重点和工作流程采用。

区域动态在塑造筹资策略、监管协调以及样本製备技术的演进中发挥关键作用。在美洲，对临床定序基础设施和转化研究中心的投资正在推动对自动化工作流程和检验套件的需求，以支援高通量和临床级操作。随着该地区的实验室专注于临床应用和大规模研究倡议，它们通常会优先考虑与现有设备的快速整合以及强大的售后支援。

在欧洲、中东和非洲，监管环境和医疗基础设施的多样性使得合规途径和区域验证至关重要。这些地区的实验室正日益寻求既能促进跨境合作又能满足严格的区域合规框架的解决方案。人们越来越关注能够适应资源丰富的城市中心和需要可靠、简化营运通讯协定的分散式设施的灵活工作流程。

在亚太地区，定序能力的快速扩张以及对基因组学主导的医疗保健和农业领域的投资，正在推动对高性价比、高通量样本製备解决方案的需求。在一些国家，本地製造和供应链措施正开始影响采购选择，促使供应商考虑区域生产和分销策略。然而，在不同地区，监管预期、报销环境和研究重点相互作用，共同决定样本製备设备、试剂和服务的投资重点。

阐述整合解决方案、伙伴关係策略和检验的绩效数据如何帮助样品製备生态系统中的供应商打造竞争优势

样品製备领域的竞争格局呈现出多元化的特点，既有成熟的仪器製造商，也有专业的试剂供应商，还有提供端到端工作流程解决方案和技术支援的服务供应商。许多领先企业专注于提供整合解决方案，将仪器与检验的试剂组和软体支援的品管捆绑在一起，从而降低终端用户的整合风险，并加速其在临床和高通量研究环境中的应用。另一些企业则专注于小众化学领域或新型萃取技术，以解决特定的难题，例如低起始量样本或高度降解的核酸。

伙伴关係和通路策略正日益成为企业差异化的核心。那些能够建立强大的经销商网路、本地技术支援以及与终端用户合作开发的供应商，能够更快地应对需求波动和监管变化。此外，对测试方法验证和已发布效能数据的投入，正成为实验室管理人员和采购团队越来越重要的决策依据。那些能够在多项独立研究中证明结果可重复性的公司，能够增强潜在买家的信心，并降低他们更换试剂或平台时所面临的风险。

创新流程也受到跨领域合作的影响。试剂公司、仪器原始设备製造商 (OEM) 和委外研发机构)之间的合作，能够打造将一流组件与託管服务相结合的模组化解决方案。这种合作模式加速了产品改进，并常常为临床和研究应用累积更广泛的依证。最终，能够显着提升工作流程效率、可重复性和生命週期支持，同时又能根据需要灵活定制的机构，将获得竞争优势。

为供应商和实验室提供切实可行的、基于实证的倡议，以增强样品製备工作流程中的检验、韧性和以客户为中心的服务交付。

产业领导者可以采取一系列切实可行的措施，从技术、商业性和营运层面巩固自身地位。首先，投资于工作流程验证和互通性测试，确保仪器、套件和耗材在各种实验室环境中都能稳定运行，从而降低客户实施风险并缩短资格确认週期。其次，透过发布独立的检验研究和提供清晰的品质控制指标，优先考虑绩效数据的透明度，使采购团队能够进行基于数据的比较，并增强客户对新解决方案的信心。

第三，透过供应商多元化、认证替代试剂形式以及发展区域分销能力，增强供应链韧性并降低贸易中断风险。第四，拓展服务范围，整合技术培训、方法转移和售后支持，以最大限度地延长执行时间并减少用户错误。第五，积极与相关人员和临床合作伙伴沟通，预测合规要求，并使产品开发与临床证据需求保持一致。透过这些倡议，各机构可以将自身定位为转化研究和诊断应用领域值得信赖的合作伙伴。

最后，采用以客户为中心的商业模式，在标准化、检验的快速部署套件与可设定的解决方案之间取得平衡，以满足特定应用的需求。这种混合模式既能支持扩充性，又能维持高阶研究计画所需的灵活性。实施这些建议将提高营运的稳健性，加强客户关係，并加速技术创新向可靠的实验室实践的转换。

我们制定了一套严谨透明的研究途径，将一手访谈、技术文献和供应商文件结合，以确保研究结果具有可操作性和可复製性。

本研究结合了来自一手访谈、技术文献和产品文件的定性和定量数据，以全面了解样品製备流程和供应商策略。一手访谈包括与实验室主任、采购负责人、试剂和仪器製造商的研发总监以及来自学术界、临床和商业领域的技术服务经理进行的结构化讨论。这些对话探讨了工作流程中的痛点、验证流程、供应商选择标准和供应链考量，从而提供了关于行业动态的第一手资讯。

二级资讯来源包括同行评审出版物、监管指导文件以及说明方法、性能特征和验证方法的製造商技术说明。分析重点在于方法的可比较性、重现性指标以及试剂和仪器选择对操作的影响。此外，调查团队还透过供应商文件和公开的技术资讯评估了产品的整合和支持，并将相关声明与实验室经验进行了交叉验证。

我们的分析框架结合了主题综合分析和跨细分维度的比较评估，旨在揭示通用的采用驱动因素、技术权衡以及供应商差异化。在整个过程中，我们专注于提供能够为策略决策提供依据的洞察，而不依赖专有的商业性估算，并且我们始终确保调查方法的透明性和可复製性。

策略要务概述：优先采用检验、可互通且具弹性的样本製备方法，以维持定序可靠性和转化应用价值。

总之，对于任何寻求可靠、高品质定序数据的机构而言，优化样品製备都是至关重要的策略重点。试剂、自动化和品质控制方面的技术改进直接关係到下游分析的可重复性和灵敏度，而供应链和监管动态则影响采购选择和营运韧性。因此，相关人员必须将样品製备视为策略性投资，因为它会影响实验成功率、实验室通量和科学发现的可靠性。

整合解决方案、区域采购协调和循证检验等趋势的整合，标誌着一个日益成熟的生态系统正在形成，该系统重视透明度、互通性和卓越服务。积极解决相容性、验证和供应连续性的组织将更有利于掌握科研机会并减少营运中断。最终，对样本製备流程和供应商伙伴关係的明智投资将带来更可靠的定序结果、加速转化应用，并增强临床和研究使用者的信心。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 微流体控平台的出现使得以最少的起始原料製备单细胞文库成为可能。
  • 开发针对cfDNA和液态生物检体样本优化的低起始量和超低起始量文库建构试剂套件
  • 将自动化和机器人技术整合到高通量NGS样品製备工作流程中以实现可扩展性
  • 采用酵素DNA片段化技术取代机械剪切法来提高文库完整性
  • 一种创新的条码和独特分子标识符方法，用于减少多重检测中的扩增偏差
  • 标靶富集探针技术的进步使得从复杂样本中高度特异性捕获罕见基因组变异成为可能。
  • 实施即时品管和标准化系统，以最大限度地减少文库製备失败
  • 端到端样本定序平台的日益普及将有助于加速临床NGS诊断流程。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章次世代定序仪样品製备市场（依产品划分）

  • 装置
  • 试剂和耗材
  • 服务

第九章 依工作流程分類的次世代定序仪样品製备市场

  • 文库製备与扩增
  • 文库定量/品质控制
  • 核酸萃取
  • 靶向序列捕获

第十章次世代定序仪样品製备市场 NGS技术

  • ChIP定序（染色质免疫沉淀定序）
  • EXOME定序
  • 甲基化定序
  • RNA定序（RNA-Seq）
  • 标靶定序
  • 全基因测序（WGS）

第十一章 按样品类型分類的次世代定序仪样品製备市场

  • DNA
  • RNA

第十二章次世代定序仪样品製备市场（依应用领域划分）

  • 农业基因组学
  • 动物科学与兽医研究
  • 临床诊断
  • 临床研究和药物开发
  • 消费者基因体学
  • 法医学

第十三章次世代定序仪样品製备市场（依最终用户划分）

  • 学术研究机构
  • 医院和诊所
  • 製药和生物技术公司

第十四章次世代定序仪样品製备市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章次世代定序仪样品製备市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国次世代定序仪样本製备市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Agilent Technologies, Inc.
    • Azenta Life Sciences
    • BGI Genomics Co., Ltd.
    • Biodiscovery, LLC
    • Bio-Rad Laboratories, Inc.
    • Charles River Laboratories International, Inc
    • Danaher Corporation
    • F. Hoffmann-La Roche Ltd
    • GenScript Biotech Corporation
    • Hamilton Bonaduz AG
    • Illumina, Inc.
    • LGC Biosearch Technologies
    • Merck KGaA
    • Meridian Bioscience, Inc
    • New England Biolabs, Inc
    • NimaGen BV
    • Omega Bio-tek, Inc.
    • Oxford Nanopore Technologies PLC
    • Pacific Biosciences of California, Inc.
    • Parse Biosciences
    • PerkinElmer, Inc.
    • Promega Corporation
    • QIAGEN NV
    • Standard BioTools Inc.
    • Takara Bio Inc.
    • Thermo Fisher Scientific, Inc.
    • Twist Bioscience Corporation
    • Zymo Research Corporation
Product Code: MRR-2214614769A0

The Next-Generation Sequencing Sample Preparation Market is projected to grow by USD 14.52 billion at a CAGR of 12.47% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.67 billion
Estimated Year [2025] USD 6.34 billion
Forecast Year [2032] USD 14.52 billion
CAGR (%) 12.47%

Introducing the strategic imperative for optimizing sample preparation workflows to safeguard data integrity, accelerate research, and enhance clinical sequencing outcomes

Next-generation sequencing (NGS) has evolved from a transformative laboratory technique into a foundational pillar for modern biology, diagnostics, and applied research. As sequencing throughput and analytical complexity have increased, the processes that precede sequencing-sample collection, nucleic acid extraction, library construction, target enrichment, and quality control-have emerged as critical determinants of data fidelity and interpretability. Robust sample preparation ensures that the biological signal of interest is preserved and presented consistently to downstream instruments, thereby reducing analytical variability and accelerating the translation of raw sequence reads into actionable insights.

This report introduces the strategic importance of sample preparation by examining the confluence of technological advancement, regulatory scrutiny, and operational demands that now shape practice in academic, clinical, and commercial laboratories. It emphasizes that improvements in reagents, automation, and protocol standardization have immediate impacts on turnaround time, reproducibility, and cost-per-result. Consequently, laboratory leaders and procurement teams must evaluate sample preparation not as a peripheral supply cost but as an integral component of the sequencing value chain.

Finally, the introduction sets the stage for deeper analysis by framing key questions for stakeholders: how do different workflows and consumables influence analytical outcomes; which innovations meaningfully reduce pre-analytical errors; and how should organizations prioritize investments to align with scientific objectives and regulatory expectations. With that framing in place, subsequent sections explore the landscape shifts, regulatory headwinds, segmentation intelligence, regional dynamics, competitive positioning, and practical recommendations that collectively inform strategic decisions.

Assessing how technological innovation, automation, and standardization are reshaping sample preparation practices and influencing laboratory operational models

The landscape of sample preparation for next-generation sequencing is undergoing rapid, multidimensional change driven by technological innovation, evolving regulatory environments, and the increasing expectations of end users for reproducible, high-quality data. Advances in reagent chemistry and enzymology are enabling more efficient library preparation with lower input requirements, thereby expanding the range of sample types that can be interrogated. Concurrently, improvements in automation and microfluidic handling are reducing manual variability and increasing throughput, which is particularly consequential as sequencing scales to population-level studies and routine clinical diagnostics.

These technological shifts are accompanied by a growing emphasis on standardization and interoperability. Inter-laboratory reproducibility is now a central metric for both clinical validation and collaborative research, prompting suppliers and laboratories to invest in validated kits, closed workflows, and integrated QC solutions. The convergence of wet-lab improvements and informatics-enabled QC checkpoints strengthens the traceability of samples from collection to data deliverables. Moreover, emerging approaches such as targeted enrichment refinement and low-input library methods are enabling new applications, including circulating tumor DNA profiling and single-cell analyses, which demand specialized sample preparation strategies.

As a result, organizations are rethinking procurement and operational models. There is a clear shift toward bundled solutions that integrate instruments, reagents, and services in order to minimize compatibility issues and accelerate time-to-result. This shift has strategic implications for suppliers and end users alike: suppliers must demonstrate workflow compatibility and regulatory readiness, while laboratories must balance flexibility for bespoke protocols against the efficiencies of standardized, validated kits and platforms. Ultimately, these transformative shifts are redefining expectations for performance, reliability, and lifecycle support across the sample preparation ecosystem.

Examining the operational and supply chain consequences of tariff changes and trade policy shifts on reagent sourcing, procurement strategies, and production continuity

Tariff changes and trade policy adjustments can exert immediate pressure on the supply chains that underpin reagents, instruments, and consumables necessary for next-generation sequencing sample preparation. In the United States, tariff measures announced or implemented in 2025 have introduced new cost considerations and logistical complexity for organizations that source specialized enzymes, plastics, and instrumentation components from international suppliers. These developments have prompted procurement teams to reassess vendor contracts, lead time buffers, and contingency inventories to mitigate disruption risk and maintain continuity of service.

In response to tariff-driven uncertainty, many stakeholders are diversifying supplier networks and exploring regional sourcing arrangements to reduce exposure to cross-border duties. Some laboratories have accelerated qualification of alternative reagent formats and vendor-agnostic consumables to preserve operational agility. At the same time, manufacturers are responding by adapting pricing strategies, localizing certain aspects of production, and expanding distributor partnerships to offset the immediate impacts of trade-related costs. These adjustments often come with transitional friction, including qualification cycles and potential variances in lot-to-lot performance that must be managed through rigorous QC protocols.

From an operational perspective, institutions are prioritizing supply chain resilience alongside scientific performance. This entails developing risk assessments that account for tariff volatility, lead time variability, and single-source dependencies. Simultaneously, procurement and laboratory leadership are increasingly collaborating to balance short-term continuity measures with long-term strategic sourcing, ensuring that sample preparation workflows remain robust in the face of ongoing policy and trade fluctuations. These collective responses underscore the importance of flexible procurement strategies and vendor engagement practices to preserve experimental integrity and service delivery.

Delivering nuanced segmentation intelligence that links product types, workflows, technologies, sample classes, applications, and end user priorities to guide procurement and development

Understanding the sample preparation landscape requires a granular view across multiple segmentation axes that influence purchasing behavior, workflow design, and technical compatibility. Based on product considerations, laboratories evaluate instruments, reagents and consumables, and services as distinct yet interdependent categories that together determine total workflow performance and vendor value propositions. Instruments set the technical baseline for throughput and automation; reagents and consumables govern chemistry performance and lot consistency; and services, including installation and method validation, enable accelerated adoption and operational reliability.

When viewed through the workflow lens, stakeholders place emphasis on library preparation and amplification, library quantification and quality control, nucleic acid extraction, and target enrichment as sequential phases where optimization can yield disproportionate benefits in data quality. Library preparation and amplification techniques are central to preserving representation and reducing bias, whereas robust quantification and QC prevent costly sequencing failures. Nucleic acid extraction remains the foundational step, with extraction efficiency and inhibitor removal critically shaping downstream success. Target enrichment approaches, meanwhile, dictate the specificity and sensitivity of downstream analyses for targeted panels and variant detection.

NGS technology segmentation further refines decision criteria; approaches such as ChIP sequencing, exome sequencing, methylation sequencing, RNA sequencing, targeted sequencing, and whole genome sequencing each impose different requirements for input quality, fragment size, and enrichment strategies. Sample type segmentation between DNA and RNA highlights divergent handling needs and stabilization protocols, with RNA workflows typically demanding more stringent preservation and QC. Application-driven priorities-ranging from agricultural genomics and animal science to clinical diagnostics, clinical research and drug development, consumer genomics, and forensics-shape validation requirements, throughput tolerances, and regulatory scrutiny. Finally, end users including academic and research institutions, hospitals and clinics, and pharmaceutical and biotechnology companies demonstrate unique purchasing rationales and service expectations, driving suppliers to offer differentiated commercial models and technical support to meet these varied needs.

Explaining how regional regulatory frameworks, infrastructure investments, and local sourcing trends shape procurement priorities and workflow adoption across global territories

Regional dynamics play a pivotal role in shaping procurement strategies, regulatory alignment, and the evolution of sample preparation practices. In the Americas, investment in clinical sequencing infrastructures and translational research hubs is fostering demand for automated workflows and validated kits that support high-throughput and clinical-grade operations. Laboratories in this region often emphasize rapid integration with existing instrumentation and robust after-sales support, reflecting the heavy focus on clinical adoption and large-scale research initiatives.

Across Europe, the Middle East & Africa, regulatory heterogeneity and varied healthcare infrastructures create a landscape where compliance pathways and localized validation are critical. Laboratories in this combined region increasingly seek solutions that facilitate cross-border collaboration while meeting stringent regional compliance frameworks. There is a pronounced interest in flexible workflows that can be adapted to both resource-rich urban centers and decentralized facilities that require reliable, low-complexity protocols.

In the Asia-Pacific region, rapid expansion of sequencing capacity and investments in genomics-driven healthcare and agriculture are driving demand for cost-effective, high-throughput sample preparation solutions. Local manufacturing and supply chain initiatives in several countries are beginning to influence procurement choices, encouraging suppliers to consider regional production and distribution strategies. Across all regions, however, the interplay between regulatory expectations, reimbursement environments, and research priorities shapes how organizations prioritize investments in instrumentation, reagents, and services for sample preparation.

Profiling how integrated solutions, partnership strategies, and validated performance data create competitive differentiation among suppliers in the sample preparation ecosystem

Competitive dynamics in the sample preparation space are characterized by a mix of established instrument manufacturers, specialized reagent suppliers, and service providers that deliver end-to-end workflow solutions and technical support. Many leading players focus on integrated offerings that bundle instruments with validated reagent kits and software-enabled quality control, thus reducing integration risk for end users and accelerating adoption in clinical and high-throughput research settings. Others specialize in niche chemistries or novel extraction technologies that address specific pain points, such as low-input samples or highly degraded nucleic acids.

Partnerships and channel strategies are becoming central to company differentiation. Suppliers that cultivate strong distributor networks, localized technical support, and co-development relationships with end users can more rapidly respond to demand variability and regulatory needs. Additionally, investments in method validation and published performance data increasingly serve as decision-making criteria for laboratory directors and procurement teams. Companies that demonstrate reproducible results across multiple independent studies enhance confidence among potential buyers and reduce the perceived risk associated with switching reagents or platforms.

Innovation pipelines are also influenced by cross-sector collaboration. Collaborations between reagent companies, instrument OEMs, and contract research organizations are enabling modular solutions that combine best-in-class components with managed services. This collaborative approach often yields accelerated product refinement and a broader evidence base for clinical and research applications. Consequently, competitive advantage accrues to organizations that can deliver demonstrable improvements in workflow efficiency, reproducibility, and lifecycle support, while maintaining flexibility for customization where necessary.

Presenting evidence-based, practical initiatives for vendors and laboratories to enhance validation, resilience, and customer-centric service delivery across sample preparation workflows

Industry leaders can adopt a set of pragmatic, actionable measures to strengthen their position across technical, commercial, and operational dimensions. First, invest in workflow validation and interoperability testing to ensure that instruments, kits, and consumables function predictably across diverse laboratory environments. This reduces implementation risk for customers and shortens qualification cycles. Second, prioritize transparency in performance data by publishing independent validation studies and providing clear QC metrics, enabling procurement teams to make evidence-based comparisons and accelerating trust in new solutions.

Third, enhance supply chain resilience by diversifying supplier bases, qualifying alternative reagent formats, and developing regional distribution capabilities to mitigate exposure to trade disruptions. Fourth, expand service offerings that combine technical training, method transfer, and post-sale support to maximize uptime and reduce user error. Fifth, engage proactively with regulatory stakeholders and clinical partners to anticipate compliance requirements and align product development with clinical evidence needs. By doing so, organizations can position themselves as trusted collaborators for translational research and diagnostic adoption.

Finally, adopt a customer-centric commercial model that balances standardized, validated kits for rapid deployment with configurable solutions for specialized applications. This hybrid approach supports scalability while preserving the flexibility required by advanced research programs. Implementing these recommendations enhances operational robustness, strengthens customer relationships, and accelerates the translation of technical innovations into reliable laboratory practice.

Outlining the rigorous, transparent research approach that integrates primary interviews, technical literature, and supplier documentation to ensure actionable and reproducible findings

This research synthesizes qualitative and quantitative inputs from primary interviews, technical literature, and product documentation to develop a comprehensive understanding of sample preparation practices and supplier strategies. Primary engagement included structured discussions with laboratory directors, procurement leads, R&D heads at reagent and instrument manufacturers, and technical service managers across academic, clinical, and commercial settings. These conversations explored workflow pain points, validation practices, vendor selection criteria, and supply chain considerations, providing first-hand context for observed industry dynamics.

Secondary sources comprised peer-reviewed publications, regulatory guidance documents, and manufacturer technical notes that describe methods, performance characteristics, and validation approaches. Analytical emphasis was placed on method comparability, reproducibility metrics, and the operational implications of reagent and instrument choices. Additionally, the research team evaluated product integration and support offerings through supplier documentation and publicly available technical information to triangulate claims with laboratory experiences.

The analytical framework combined thematic synthesis with comparative evaluation across segmentation axes to identify common drivers of adoption, technical trade-offs, and supplier differentiation. Throughout the process, attention was paid to ensuring methodological transparency and reproducibility of findings, with a focus on delivering insights that inform strategic decisions without relying on proprietary commercial estimations.

Summarizing the strategic imperative to prioritize validated, interoperable, and resilient sample preparation practices to sustain sequencing reliability and translational impact

In conclusion, optimizing sample preparation is an indispensable strategic priority for any organization seeking reliable, high-quality sequencing data. Technical refinements in reagents, automation, and QC have a direct bearing on the reproducibility and sensitivity of downstream analyses, while supply chain and regulatory dynamics shape procurement choices and operational resilience. Stakeholders must therefore evaluate sample preparation as a strategic investment that influences experiment success rates, laboratory throughput, and the credibility of scientific findings.

The converging trends toward integrated solutions, regional sourcing adjustments, and evidence-based validation signal a maturing ecosystem that rewards transparency, interoperability, and service excellence. Organizations that proactively address compatibility, validation, and supply continuity will be better positioned to capitalize on scientific opportunities and to mitigate operational disruptions. Ultimately, judicious investments in sample preparation practices and supplier partnerships translate into more reliable sequencing outputs, accelerated translational impact, and enhanced confidence among clinical and research users.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of microfluidic-based platforms enabling single-cell library preparation with minimal input requirements
  • 5.2. Development of low-input and ultra-low-input library kits optimized for cfDNA and liquid biopsy samples
  • 5.3. Integration of automation and robotics in high-throughput NGS sample preparation workflows for scalability
  • 5.4. Adoption of enzymatic DNA fragmentation techniques replacing mechanical shearing to improve library integrity
  • 5.5. Innovative barcoding and unique molecular identifier approaches to reduce amplification bias in multiplex assays
  • 5.6. Advances in targeted enrichment probes enabling highly specific capture of rare genomic variants from complex samples
  • 5.7. Implementation of real-time quality control and normalization systems to minimize library preparation failures
  • 5.8. Growing adoption of end-to-end sample-to-sequencer platforms to accelerate clinical NGS diagnostic pipelines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next-Generation Sequencing Sample Preparation Market, by Product

  • 8.1. Instruments
  • 8.2. Reagents & Consumables
  • 8.3. Services

9. Next-Generation Sequencing Sample Preparation Market, by Workflow

  • 9.1. Library Preparation & Amplification
  • 9.2. Library Quantification/QC
  • 9.3. Nucleic Acid Extraction
  • 9.4. Target Enrichment

10. Next-Generation Sequencing Sample Preparation Market, by NGS Technology

  • 10.1. ChIP Sequencing (Chromatin Immunoprecipitation)
  • 10.2. Exome Sequencing
  • 10.3. Methylation Sequencing
  • 10.4. RNA Sequencing (RNA-Seq)
  • 10.5. Targeted Sequencing
  • 10.6. Whole Genome Sequencing (WGS)

11. Next-Generation Sequencing Sample Preparation Market, by Sample Type

  • 11.1. DNA
  • 11.2. RNA

12. Next-Generation Sequencing Sample Preparation Market, by Application

  • 12.1. Agricultural Genomics
  • 12.2. Animal Science & Veterinary Research
  • 12.3. Clinical Diagnostics
  • 12.4. Clinical Research & Drug Development
  • 12.5. Consumer Genomics
  • 12.6. Forensics

13. Next-Generation Sequencing Sample Preparation Market, by End User

  • 13.1. Academic & Research Institutions
  • 13.2. Hospitals & Clinics
  • 13.3. Pharmaceutical & Biotechnology Companies

14. Next-Generation Sequencing Sample Preparation Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Next-Generation Sequencing Sample Preparation Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Next-Generation Sequencing Sample Preparation Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Agilent Technologies, Inc.
    • 17.3.2. Azenta Life Sciences
    • 17.3.3. BGI Genomics Co., Ltd.
    • 17.3.4. Biodiscovery, LLC
    • 17.3.5. Bio-Rad Laboratories, Inc.
    • 17.3.6. Charles River Laboratories International, Inc
    • 17.3.7. Danaher Corporation
    • 17.3.8. F. Hoffmann-La Roche Ltd
    • 17.3.9. GenScript Biotech Corporation
    • 17.3.10. Hamilton Bonaduz AG
    • 17.3.11. Illumina, Inc.
    • 17.3.12. LGC Biosearch Technologies
    • 17.3.13. Merck KGaA
    • 17.3.14. Meridian Bioscience, Inc
    • 17.3.15. New England Biolabs, Inc
    • 17.3.16. NimaGen B.V.
    • 17.3.17. Omega Bio-tek, Inc.
    • 17.3.18. Oxford Nanopore Technologies PLC
    • 17.3.19. Pacific Biosciences of California, Inc.
    • 17.3.20. Parse Biosciences
    • 17.3.21. PerkinElmer, Inc.
    • 17.3.22. Promega Corporation
    • 17.3.23. QIAGEN N.V.
    • 17.3.24. Standard BioTools Inc.
    • 17.3.25. Takara Bio Inc.
    • 17.3.26. Thermo Fisher Scientific, Inc.
    • 17.3.27. Twist Bioscience Corporation
    • 17.3.28. Zymo Research Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY LIBRARY PREPARATION & AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY LIBRARY PREPARATION & AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY LIBRARY PREPARATION & AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY LIBRARY PREPARATION & AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY LIBRARY PREPARATION & AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY LIBRARY PREPARATION & AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY LIBRARY QUANTIFICATION/QC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY LIBRARY QUANTIFICATION/QC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY LIBRARY QUANTIFICATION/QC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY LIBRARY QUANTIFICATION/QC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY LIBRARY QUANTIFICATION/QC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY LIBRARY QUANTIFICATION/QC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NUCLEIC ACID EXTRACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NUCLEIC ACID EXTRACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NUCLEIC ACID EXTRACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NUCLEIC ACID EXTRACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NUCLEIC ACID EXTRACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NUCLEIC ACID EXTRACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY TARGET ENRICHMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY TARGET ENRICHMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY TARGET ENRICHMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY TARGET ENRICHMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY TARGET ENRICHMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY TARGET ENRICHMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CHIP SEQUENCING (CHROMATIN IMMUNOPRECIPITATION), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CHIP SEQUENCING (CHROMATIN IMMUNOPRECIPITATION), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CHIP SEQUENCING (CHROMATIN IMMUNOPRECIPITATION), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CHIP SEQUENCING (CHROMATIN IMMUNOPRECIPITATION), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CHIP SEQUENCING (CHROMATIN IMMUNOPRECIPITATION), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CHIP SEQUENCING (CHROMATIN IMMUNOPRECIPITATION), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY EXOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY EXOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY EXOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY EXOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY EXOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY METHYLATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY METHYLATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY METHYLATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY METHYLATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY METHYLATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY METHYLATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY RNA SEQUENCING (RNA-SEQ), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY RNA SEQUENCING (RNA-SEQ), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY RNA SEQUENCING (RNA-SEQ), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY RNA SEQUENCING (RNA-SEQ), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY RNA SEQUENCING (RNA-SEQ), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY RNA SEQUENCING (RNA-SEQ), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY DNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY DNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY DNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY DNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY DNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY RNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY RNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY RNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY RNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY RNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY RNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY AGRICULTURAL GENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY AGRICULTURAL GENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY AGRICULTURAL GENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY AGRICULTURAL GENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY AGRICULTURAL GENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY AGRICULTURAL GENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY ANIMAL SCIENCE & VETERINARY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY ANIMAL SCIENCE & VETERINARY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY ANIMAL SCIENCE & VETERINARY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY ANIMAL SCIENCE & VETERINARY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY ANIMAL SCIENCE & VETERINARY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY ANIMAL SCIENCE & VETERINARY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CLINICAL RESEARCH & DRUG DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CLINICAL RESEARCH & DRUG DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CLINICAL RESEARCH & DRUG DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CLINICAL RESEARCH & DRUG DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CLINICAL RESEARCH & DRUG DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CLINICAL RESEARCH & DRUG DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CONSUMER GENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CONSUMER GENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CONSUMER GENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CONSUMER GENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CONSUMER GENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CONSUMER GENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY FORENSICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY FORENSICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY FORENSICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY FORENSICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY FORENSICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY FORENSICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2024 (U